

## Drivers of disengagement from care during the first six months on antiretroviral therapy for HIV in South Africa: a mixed-methods study

Mhairi Maskew<sup>1§</sup>, Nyasha Mutanda<sup>1</sup>, Nancy Scott<sup>2</sup>, Allison Morgan<sup>2</sup>, Mariet Benade<sup>1,2,3</sup>, Vinolia Ntjikelane<sup>1</sup>, Linda Sande<sup>1</sup>, Lufuno Malala<sup>4</sup>, Musa Manganye<sup>4</sup>, Sydney Rosen<sup>1,2</sup>

### Institutional affiliations:

<sup>1</sup>Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

<sup>2</sup>Department of Global Health, Boston University School of Public Health, Boston, MA, USA

<sup>3</sup>Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

<sup>4</sup>HIV/AIDS Treatment, Care and Support, South African National Department of Health, Pretoria, South Africa

<sup>§</sup>**Corresponding author:** Mhairi Maskew

Health Economics and Epidemiology Research Office, 32 Princess of Wales Terrace, Parktown, Johannesburg, 2193, South Africa.

Tel +27 010 001 7930

Email: [mmaskew@heroza.org](mailto:mmaskew@heroza.org).

### Email addresses of authors:

Author	E-mail	ORCID ID
Mhairi Maskew	<a href="mailto:mmaskew@heroza.org">mmaskew@heroza.org</a>	0000-0003-4238-0200
Nyasha Mutanda	<a href="mailto:nmutanda@heroza.org">nmutanda@heroza.org</a>	0000-0002-2464-5124
Nancy Scott	<a href="mailto:nscott@bu.edu">nscott@bu.edu</a>	0000-0002-4713-4642
Allison Morgan	<a href="mailto:juntunen@bu.edu">juntunen@bu.edu</a>	0000-0001-8877-5107
Mariet Benade	<a href="mailto:mbenade@bu.edu">mbenade@bu.edu</a>	0000-0001-9498-3199
Vinolia Ntjikelane	<a href="mailto:vntjikelane@heroza.org">vntjikelane@heroza.org</a>	0009-0003-2805-6890
Linda Sande	<a href="mailto:lsande@heroza.org">lsande@heroza.org</a>	0009-0003-4230-5961
Lufuno Malala	<a href="mailto:lufuno.malala@health.gov.za">lufuno.malala@health.gov.za</a>	0009-0001-7695-3671
Musa Manganye	<a href="mailto:Musa.Manganye@health.gov.za">Musa.Manganye@health.gov.za</a>	0000-0001-8420-0613
Sydney Rosen	<a href="mailto:sbrosen@bu.edu">sbrosen@bu.edu</a>	0000-0002-6560-2964

### Keywords:

HIV, South Africa, antiretroviral therapy, retention, cohort study, mixed-methods

### Word count:

Abstract: 342/350

Main text: 5701/5000 (includes Table 5 in word count)

1 **Abstract**

2 **Introduction:** For clients on HIV treatment in sub-Saharan Africa, disengagement from HIV care in the  
3 early treatment period is a critical obstacle to achieving UNAIDS's second 95 target. While South Africa's  
4 Differentiated Service Delivery Guideline on Fast Track Initiation and Counseling (FTIC) define normative  
5 procedures, the effect of guideline implementation and the underlying drivers of disengagement remain  
6 unclear.

7  
8 **Methods:** The PREFER mixed-methods study enrolled a prospective cohort of adult clients initiating ART,  
9 returning to care after a period of disengagement or already on ART for  $\leq 6$  months at 18 public sector  
10 healthcare facilities in South Africa. A survey collected data on demographic and clinical characteristics  
11 and preferences of participants who were followed up through routinely-collected medical visit records  
12 for up to 7 months after treatment initiation to estimate continuity of HIV care (attended all scheduled  
13 visits within 28 days). Focus group discussions (FGDs) were conducted approximately 12 months after  
14 enrollment among a subset of participants who had expressed concerns about treatment retention.

15  
16 **Results:** During the study period 7/9/2022-30/6/2023, PREFER-SA enrolled 1,049 participants (72%  
17 female, median age=33 years, 24% with CD4 count $<200$ cells/mm<sup>3</sup>); 122 of whom also participated in  
18 focus group discussions. By 6 months on ART, 23% were not continuously in HIV care. Those newly  
19 initiating ART at study enrollment were more likely to have disengaged or interrupted treatment by 6  
20 months as those who had remained in care for  $\geq 1$  visit. Disengagement was also more likely among men  
21 and younger (18-24 years) participants, those reporting food scarcity, and those initiated on regimens  
22 other than Dolutegravir. Disengagement did not differ by gender, relationship status, or CD4 count.  
23 Qualitative FGD results suggest participants experience barriers to adherence within and between all  
24 levels of the socio-ecologic model. Challenges related to the facility experience were most prominent.

25  
26 **Conclusions:** Among adults initiating or re-initiating ART in South Africa, the highest risk of  
27 disengagement is immediately after initiation. We identified several potentially modifiable individual and  
28 social characteristics associated with early disengagement. Improving the patient facility experience and  
29 strengthening implementation of SA's Service Delivery Guidelines may increase retention during the  
30 early treatment period.

31  
32 **Word count:** 342 words

### 33 **Introduction**

34

35 The successful implementation of universal access to antiretroviral therapy (ART) for HIV treatment has  
36 achieved global targets for reaching clients living with HIV in many African countries with high burdens of  
37 HIV. Despite these successes, optimal outcomes for HIV treatment have not yet been achieved, due to  
38 losses from care after ART initiation. The first six months after ART initiation, dubbed the “early  
39 retention” period[1], remain the period of highest risk for interruption or disengagement[2]. In a recent  
40 study in South Africa that relied on routinely collected electronic medical record (EMR) data, 16% of ART  
41 initiators had disengaged by 6 months. Another 14% had experienced an interruption of more than 28  
42 days during that period, before returning to care, and an interruption in the early treatment period was a  
43 strong predictor of disengagement between 7 and 12 months, with a relative risk of disengagement of  
44 1.76 compared to those who had not interrupted[3].

45

46 In addition to the challenges associated with starting any new kind of chronic medical care, achieving  
47 retention in care during the early treatment period requires overcoming some specific barriers. Clients  
48 presenting for ART initiation fall generally into three categories. The first category comprises the quarter  
49 to a third of clients who continue to present for treatment initiation with very low CD4 counts[4,5] or in  
50 WHO stage III or IV requiring additional clinical care for advanced HIV disease (AHD) [6]. The second  
51 category is for the high proportion of patients who have prior ART experience and are re-initiating ART  
52 after previously disengaging from care. Recent studies indicate that half or more of those who present  
53 for "initiation" in South Africa have prior ART experience[7,8]. Individuals who know their status and  
54 have already started and stopped ART at least once (re-initiators) may face the same barriers to  
55 retention again, if they have not received intervention related to those barriers. Re-initiators often  
56 present with AHD as well. Finally, the third category includes naive initiators with higher CD4 counts and  
57 in WHO stage I or II. Starting CD4 counts have climbed steadily since the introduction of universal  
58 treatment in 2016 for those who do not have AHD[9]. In the contemporary era these clients, who are the  
59 prototypical patient for whom guidelines were originally designed, likely comprise only a third or fewer  
60 of those presenting for treatment initiation.

61

62 Because of their high risk of disengagement, more attention is needed to all three of the categories of  
63 early treatment clients. Neither of the major treatment cascade-related service delivery innovations of  
64 the past decade--same-day initiation of ART [10] and differentiated models of HIV care for clients

65 established and stable on ART [11]--address the early treatment period. Research on retention in HIV  
66 care, moreover, has generally focused on long-term attrition from care, regarding the first six months as  
67 a uniform period that marks the shortest interval before a measurable outcome (retention or viral  
68 suppression) can be assessed[12]. Research is needed to identify and understand potential drivers of  
69 disengagement during the early treatment period so that client-appropriate interventions can be  
70 developed. Here, employing a mixed-methods approach to characterize the early treatment period in  
71 South Africa, we identify associations between client characteristics and early treatment outcomes in the  
72 PREFER study and explore client perceptions of barriers to adherence in their first six months on  
73 treatment.

74

## 75 **Methods**

76

### 77 *Study design*

78 PREFER was an observational, prospective cohort study conducted in South Africa (7 September 2022 -  
79 30 June 2023) that aimed to describe and understand the needs of clients both newly initiating and re-  
80 initiating ART in order to inform the design of DSD models for the early HIV treatment period and  
81 improve early treatment outcomes[13]. During the study period, clients presenting for ART initiation or  
82 re-initiation or on ART for less than 6 months (i.e. within 6 months of initiation) were enrolled during a  
83 routine HIV care clinic visit and administered a baseline survey with quantitative and open-ended  
84 questions. Follow up included passive medical record review and participation by a subsample of survey  
85 responders in focus group discussions (FGDs).

86

### 87 *Study sites and population*

88 PREFER was conducted at 18 healthcare facilities in South Africa that had large ART client volumes and  
89 utilized the national electronic medical record system for HIV (TIER.Net). The study sequentially enrolled  
90 clients that were  $\geq 18$  years old, initiating, re-initiating, or on ART for  $\leq 6$  months and were able to provide  
91 written informed consent. Consent included participation in the baseline survey, permission to access  
92 medical records, and agreement to be contacted for follow-up within 12 months if more information was  
93 sought. During screening, clients who were unwilling to take the time required to complete the survey  
94 on the day of consent, unable to communicate in one of the languages into which the survey was  
95 translated, or judged by clinic or study staff to be physically or emotionally unable to provide consent or  
96 participate in all study procedures were excluded.

97  
98 During the period of PREFER enrollment, the 2019/2020 South African ART guidelines were in place.  
99 They recommended a standard first-line ARV regimen of tenofovir, emtricitabine and dolutegravir  
100 [14,15]. Standard of care for the first six months on ART South Africa included 5-7 facility visits for clinical  
101 consultation, laboratory tests, and medication dispensing, with the first routine viral load (VL) test  
102 conducted at 6 months post initiation. Eligibility for less intensive models of care (sometimes known as  
103 differentiated models) required at least 6 months' experience on ART and documentation of a  
104 suppressed viral load, making early treatment clients ineligible for South Africa's repeat prescription  
105 strategies[14,15]. (We note that new guidelines were issued in 2023 and have revised the schedule for  
106 the early treatment period and eligibility criteria for less intensive models of care[16]; these are  
107 discussed further below.)

#### 108 109 *Data sources, recruitment, and enrollment*

110  
111 The PREFER survey instrument was an interviewer-administered structured questionnaire that collected  
112 self-reported data on a client's demographic characteristics and socio-economic status, HIV testing  
113 history, HIV treatment history, current HIV care and treatment experience, other healthcare, preferences  
114 for treatment delivery, expectations, and costs of seeking care[13]. Participants were then passively  
115 followed up through EMR data from TIER.Net and South Africa's National Health Laboratory Services  
116 database and from paper records and registers maintained at the study sites.

117  
118 At the study sites, clinic staff informed potentially eligible clients that they may be eligible to participate  
119 in a research study when the patient checked in at the reception desk. Clients were recruited  
120 consecutively as they arrived at each facility, based on availability of study interviewers.

121  
122 Roughly one year after the baseline survey, a subset of those who consented to follow-up were invited to  
123 participate in a qualitative FGD to explore participant experience in the early treatment period.

124 Approximately 15 FGDs, each with 8-12 participants, were conducted in selected PREFER study facilities  
125 chosen to capture both urban and rural populations. We aimed for a maximum of 180 participants, a  
126 sample size that was expected to reach saturation in interview themes, after which no new insights  
127 would reasonably be expected to emerge. FGD participants were purposively invited based on responses  
128 to the PREFER quantitative survey that indicated they anticipated experiencing, or had already

129 experienced, challenges to adherence in the first six months. These included having missed a scheduled  
 130 clinic visit by 2-3 days in the past, anticipating difficulty in taking daily medication or picking up  
 131 medications, or reporting that the care that they received in the clinic was worse than they had  
 132 expected. FGD guides were designed to elicit perspectives on the challenges faced by clients and factors  
 133 that enabled adherence in the early treatment period[13]. Focus groups were conducted by two study  
 134 research assistants, one of whom served as the moderator.

135

136 *Outcomes and statistical analysis*

137

138 The primary outcome for this analysis was retention in HIV care by 6 months after ART initiation. We  
 139 classified retention into three patterns of engagement derived from observed visit attendance at  
 140 scheduled clinical or medication pickup visits during the first 6 months after initiation: (i) **continuously in**  
 141 **care** if all scheduled visits during the first 6 months after initiation were observed within 28 days of  
 142 scheduled visit date or the client record indicated a documented transfer to another care facility prior to  
 143 the 6-month outcome date; (ii) **not continuously in care--disengaged** if no visits were observed in the  
 144 EMR after ART initiation, or at least one additional visit post initiation was observed but the last  
 145 scheduled visit was not attended and no further visits were observed in the EMR, or a known date of  
 146 death was documented in the EMR; or (iii) **not continuously engaged in care--cyclical** if at least one visit  
 147 post initiation was attended >28 days after the scheduled visit date (Table 1).

148

149 **Table 1: Retention in care outcome definitions**

150

Pattern	Sub-pattern	Definitions
Continuously in care	In care	All scheduled visits during the first 6 months after initiation observed within 28 days of scheduled visit date
	Transferred	Documented transfer to another care facility prior to 6-month date
Not continuously in care--disengaged	Died	Documented date of death in EMR prior to 6-month date
	Immediately disengaged	No visit after the ART initiation visit observed in the EMR
Not continuously in care--cyclical	Disengaged from care during first 6 months on ART	≥1 visit after ART initiation visit observed in the EMR; last scheduled visit in 6-month period not attended
	Treatment interruption followed by re-engagement in care by 6 months on ART	≥1 visit after ART initiation visit attended >28 days late during the first 6 months on ART

151

152 Our secondary outcome was HIV viral load (VL) suppression by 6 months on ART. To account for newly  
 153 updated South African guidelines recommending VL testing as early as 3 months after ART initiation,

154 which came into effect during our enrollment period [16], we included any VL test result observed in  
155 months 3-7 after initiation. We then classified each viral load result observed into one of three  
156 suppression categories: 1) VL suppressed (VL test result <50 copies/mL); 2) low grade viraemia (VL test  
157 result 50-1000 copies/mL; or 3) VL unsuppressed (VL test result >1000 copies/mL).

158  
159 We first describe characteristics and crude outcomes of enrolled participants using frequencies and  
160 simple proportions for categorical variables and medians with interquartile ranges for continuous  
161 variables. We then report the crude analysis showing simple proportions with 95% confidence intervals  
162 of patients not continuously in care at 6 months on ART and VL suppression results. Next, we present a  
163 simple unadjusted comparison of outcome groups (continuously or not continuously in care at 6 months)  
164 with respect to baseline predictors of outcomes. Potential predictors included demographic and clinical  
165 variables, preferences and experiences reported in the PREFER survey as well as geographic and facility-  
166 level factors (urban vs rural setting, facility type). Finally, we use a log-linear regression model to  
167 estimate crude risk ratios and their corresponding 95% confidence intervals and utilize the change-in-  
168 estimate approach to estimate an adjusted model.

169  
170 *Qualitative analysis*

171  
172 For qualitative data analysis, we used a combination inductive-deductive approach to develop a  
173 codebook to align the FGD guide, the quantitative survey, and the published literature. Two coders  
174 coded an initial set of transcripts and compared coding to ensure consistency. Discrepancies were  
175 resolved together, and one coder completed coding the remaining transcripts.

176  
177 We conducted a content analysis and situated the emergent themes within the Socio-Ecological Model  
178 (SEM) framework to understand barriers and facilitators within and between levels The SEM positions  
179 individuals within layers of influence [17], such as individual (e.g. one's age, income, health history, etc.);  
180 interpersonal (e.g. family relationships and interactions, social support); community (e.g. social  
181 networks, community sentiments, belonging, built environment); and societal (e.g. policy, social norms,  
182 economic opportunity, etc.). Such influences interact with each other in positive and negative ways and  
183 together shape peoples' lived experiences. The model has been used by researchers and stakeholders to  
184 understand contributors to poor health and identify opportunity for health delivery and promotion[18].  
185 We adapted the SEM for our population to identify barriers at the individual, interpersonal, health

186 facility, and community levels to understand how facility operations and community sentiments affect  
187 clients' care-seeking behaviors. Emergent FGD themes are presented with accompanying illustrative  
188 quotes and triangulated with quantitative findings within the results and discussion.

189

190 *Ethics review*

191

192 The PREFER study was approved by the Boston University Institutional Review Board (South Africa H-  
193 42726, May 20, 2022) and by the University of the Witwatersrand Human Research Ethics Committee  
194 (South Africa M220440, August 23, 2022). The protocol for South Africa was approved by Provincial  
195 Health Research Committees through the National Health Research Database for each study district  
196 (August 1, 2022 for West Rand; September 1, 2022 for King Cetshwayo and August 28, 2022 for  
197 Ehlanzeni). The study is registered with ClinicalTrials.gov (NCT05454839).

198

## 199 **Results**

200

201 *Characteristics of enrolled study participants*

202


203 During the study enrollment period (7 September 2022 - 30 June 2023), we screened a total of 1,115  
204 potential participants and enrolled 1,098 (Figure 1). Clients who refused consent (n=1) or had enrolled  
205 previously (n=11) were excluded, as were those who had been on ART for >6 months at screening date.  
206 An additional 2 clients were enrolled but their survey data were not completed and they were excluded  
207 from further analysis. A total of 1,049 participant records were successfully linked to the EMR and  
208 included in the final analytic sample to ascertain 6-month retention outcomes. We identified 481 clients  
209 eligible to participate in focus group discussions, of whom 155 were contacted; 122 were enrolled in 15  
210 FGDs and 32 declined. Reasons for not participating included working and not available during the week  
211 (n=10); relocation (n=9); unable to confirm a date available (n=5); not interested (n=3); medical reasons  
212 (n=2); and failure to arrive despite accepting (n=3).

213

214 **Figure 1: PREFER study enrolment flow chart**



215



216

217

218 Table 2 presents the demographic and socioeconomic characteristics of 1,049 enrolled participants  
219 included in the 6-month outcomes analysis. The final linked sample did not differ substantively from the  
220 analytic sample with respect to baseline covariates. A majority of participants were female (72%); the  
221 median age was 33 years (IQR 27-40 years). More than half of participants were unemployed and  
222 reported that access to money for healthcare would be difficult. Over 40% were initiating or reinitiating  
223 ART on the day of study enrolment, and a quarter had presented for ART initiation with a CD4 count  
224 <200cells/mm<sup>3</sup>. FGD participants were primarily female (84%) and had generally similar demographic  
225 characteristics to the full analytic sample, despite being deliberately selected because they had  
226 anticipated or experienced barriers to adherence.

227

228 **Table 2: Demographic and socio-economic characteristics of enrolled participants**

229

Characteristic	Final linked sample (n=1,049)	Qualitative FGD sample (n=123)
Age (median, IQR)	33 (27, 40)	33 (28, 41)
Gender (n, % female)	750 (71%)	101 (83%)
Marital status		
Live with primary partner	334 (32%)	34 (28%)
Do not live with a partner	488 (47%)	59 (48%)
Do not have a partner/spouse	227 (22%)	29 (24%)
Education level		
Primary or less	395 (38%)	38 (31%)
Secondary	501 (48%)	66 (54%)
Post-secondary	153 (15%)	18 (15%)
Employment status		
Formal employment	228 (22%)	15 (12%)
Informal employment	206 (20%)	24 (20%)
Unemployed	538 (51%)	73 (60%)
Student/trainee	77 (7%)	10 (8%)
Food scarcity		
Never/seldom	805 (77%)	90 (74%)
Sometimes/often	244 (23%)	32 (26%)
Access to R100 (\$6) for healthcare if needed		
Easy	23 (47%)	45 (37%)
Difficult	26 (53%)	77 (63%)
District		
West Rand	349 (33%)	40 (33%)
Ehlanzeni	350 (33%)	32 (26%)
King Cetshwayo	350 (33%)	50 (41%)
Urban/rural facility		
Rural	481 (46%)	50 (41%)
Urban	568 (54%)	72 (59%)
ART status at study enrolment		
Self-reported newly initiating	296 (28%)	35 (29%)
Self-reported re-engaging	157 (15%)	21 (17%)
On treatment	596 (57%)	66 (54%)
WHO staging at initiation		
Stage 1	904 (86%)	96 (79%)
Stage 2	82 (8%)	11 (9%)
Stages 3 and 4	41 (4%)	4 (3%)
Unknown	22 (2%)	11 (9%)
Baseline CD4 count		
CD4 count <200 cells	255 (24%)	83 (68%)
CD4 count >200 cells	686 (65%)	21 (17%)
Missing CD4 count	108 (10%)	18 (15%)
Baseline regimen		
Tenofovir//Lamivudine/Dolutegravir	946 (90%)	104 (85%)
Tenofovir/Emtricitabine//Efavirenz	84 (8%)	10 (8%)
Other	19 (2%)	0 (0%)
Missing	0 (0%)	8 (7%)

230

231 *Retention and viral load suppression outcomes*

232

233 At 6 months after ART initiation, 815 of the 1,049 participants (77%) were considered continuously in  
 234 care, 92 (9%) had disengaged from care, and 142 (14%) had a cyclical pattern of engagement (Table 3).  
 235 The proportion continuously in care included 45 individuals (4%) who had formally transferred to other  
 236 facilities. Disengagement was comprised of immediate disengagers (no visits after initiation, 3%) and  
 237 those who did not return after the first post-initiation visit (6%), along with a small number of deaths  
 238 (0.5%). Cyclical engagement was common, as anticipated from previous research[3].

239  
 240 A third of participants (33%) did not have a VL test during the first 6 months on ART, due largely to early  
 241 mortality, transfer, or disengagement from care. Cyclical engagers were also less likely than continuous  
 242 engagers to have a VL test despite returning to care after a treatment interruption and were less likely to  
 243 achieve viral suppression.

244

245 **Table 3: Retention and VL suppression outcomes stratified by pattern of engagement**

246

Outcome	Outcome definition	N, %	VL test observed	VL <50 copies/mL	VL 50-1000 copies/mL	VL >1000 copies/mL
<b>N</b>		<b>1,049 (100%)</b>	<b>705 (67%)</b>	<b>498 (47%)</b>	<b>149 (14%)</b>	<b>58 (6%)</b>
Continuously in care	In care	770 (73%)	601 (78%)	432 (72%)	130 (22%)	39 (6%)
	Transferred	45 (4%)	5 (11%)	2 (40%)	3 (60%)	0 (0%)
Disengaged	Died	4 (0.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Immediately disengaged	30 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Disengaged from care during first 6 months after ART initiation	58 (5.5%)	1 (2%)	0 (0%)	1 (100%)	0 (0%)
Cyclical engagement	Treatment interruption followed by re-engagement in care by 6 months after ART initiation	142 (14%)	98 (69%)	64 (65%)	15 (15%)	19 (19%)

247

248

249 *Predictors of retention outcomes*

250

251 We found several potential predictors of retention at 6 months after initiation (Table 4). Women had a  
 252 lower risk of disengagement during the first six months than their male counterparts (adjusted relative  
 253 risk (ARR) 0.76; 95% CI 0.59-0.98). Those who reported experiencing food scarcity were more likely to  
 254 not remain continuously in care compared to clients who reported consistent access to food (RR = 1.31;  
 255 95% CI 1.02-1.67). Clients who reported newly initiating ART had a higher risk (RR = 1.47; 95% CI 1.02-  
 256 2.12) of not continuing in care than did those who had attended at least one post-initiation visit at the

257 time of study enrolment. Though our estimates lacked precision, results also suggested that clients with  
 258 CD4 counts <200 cells/mm<sup>3</sup> at initiation were more likely to remain in care at 6 months than those with  
 259 higher CD4 counts at ART start. Young adults aged 18-24 years also appeared more likely to not be  
 260 continuously in care at 6 months on ART compared to older clients. Disengagement was higher among  
 261 clients on an Efavirenz-containing regimen than for those on Dolutegravir (RR = 1.79; 95% CI 1.21-2.66).  
 262 We did not observe important differences in retention by level of education, or relationship status or  
 263 other self-reported preferences or experiences of HIV service delivery.

264

265 **Table 4: Predictors of disengagement during the first six months on ART treatment**

266

Characteristic	Continuously in care	Not continuously in care	Crude RR (95% CI)	Adjusted RR (95% CI)*
N	815	234		
<b>Individual characteristics</b>				
Age				
≥25 years	683 (79%)	185 (21%)	Ref	Ref
18-24 years	132 (73%)	49 (27%)	1.27 (0.97 - 1.67)	1.24 (0.93 - 1.65)
Gender				
Male	224 (75%)	75 (25%)	Ref	Ref
Female	591 (79%)	159 (21%)	0.85 (0.67-1.07)	0.76 (0.59 - 0.98)
Educational level				
Secondary/ tertiary	512 (78%)	142 (22%)	Ref	Ref
Primary or less	303 (77%)	92 (23%)	1.07 (0.85 - 1.35)	1.09 (0.87 – 1.38)
Relationship status				
Have a partner	259 (78%)	75 (22%)	Ref	Ref
No partner/not living with a partner	556 (78%)	159 (22%)	0.99 (0.78 - 1.26)	1.00 (0.79 – 1.29)
Food scarcity				
Never/seldom	639 (79%)	166 (21%)	Ref	Ref
Sometimes/often	176 (72%)	68 (28%)	1.35 (1.06 - 1.72)	1.31 (1.02 - 1.67)
Can obtain ZAR100 cash for health care when required				
Easy	360 (78%)	100 (22%)	Ref	Ref
Difficult	455 (77%)	134 (23%)	1.05 (0.83 - 1.32)	1.04 (0.83 - 1.31)
Urban/rural facility				
Urban	441 (78%)	127 (22%)	Ref	Ref
Rural	374 (78%)	107 (22%)	0.99 (0.79 - 1.25)	1.02 (0.81 - 1.29)
<b>HIV care and experiences</b>				
ART status at study enrolment				
On treatment < 6 months	482 (81%)	114 (19%)	Ref	Ref
Newly initiating	208 (70%)	88 (30%)	1.55 (1.22 – 1.98)	1.54 (1.20 -1.97)
Re-engaging	125 (80%)	32 (20%)	1.07 (0.75 – 1.51)	1.05 (0.74 - 1.49)
WHO staging at initiation				
Stage1	703 (78%)	201 (22%)	Ref	Ref
Stage2	63 (77%)	19 (23%)	1.04 (0.69 - 1.57)	1.13 (0.75 - 1.73)
Stage 3 or 4	32 (78%)	9 (22%)	0.99 (0.55 - 1.78)	1.07 (0.58 - 1.95)

Characteristic	Continuously in care	Not continuously in care	Crude RR (95% CI)	Adjusted RR (95% CI)*
Unknown	17 (77%)	5 (23%)	1.02 (0.47 - 2.23)	1.03 (0.48 - 2.24)
Baseline CD4 count				
≥200 copies	525 (77%)	161 (23%)	Ref	Ref
<200 copies	207 (81%)	48 (19%)	0.80 (0.60 - 1.07)	0.79 (0.58 - 1.07)
Missing	83 (77%)	25 (23%)	0.99 (0.68 - 1.43)	1.05 (0.72 - 1.54)
Baseline regimen				
Tenofovir/Lamivudine/Dolutegravir	742 (78%)	204 (22%)	Ref	Ref
Tenofovir/Emtricitabine/Efavirenz	58 (69%)	26 (31%)	1.44 (1.02 - 2.02)	1.79 (1.21 - 2.66)
Other	15 (79%)	4 (21%)	0.98 (0.41 - 2.35)	1.18 (0.48 - 2.89)
<b>Preferences</b>				
Do you wish that this clinic offered you more/the same/less HIV information?				
Same or less	418 (78%)	121 (22%)	Ref	Ref
More	397 (78%)	113 (22%)	0.99 (0.79 - 1.24)	1.00 (0.80 - 1.25)
Do you wish that this clinic offered you more/ the same/less counselling?				
Same or less	420 (78%)	116 (22%)	Ref	Ref
More	395 (77%)	118 (23%)	1.06 (0.85 - 1.33)	1.06 (0.85 - 1.32)
I prefer to attend clinic visits				
Alone	705 (78%)	195 (22%)	Ref	Ref
With someone	110 (74%)	39 (26%)	1.21 (0.90 - 1.63)	1.12 (0.82 - 1.51)
I prefer to receive HIV treatment outside the clinic				
No	289 (78%)	81 (22%)	Ref	Ref
Yes	526 (77%)	153 (23%)	1.03 (0.81 - 1.31)	1.05 (0.83 - 1.33)
<b>Facility experience</b>				
Some staff do not treat patients with sufficient respect				
Disagree	611 (78%)	171 (22%)	Ref	Ref
Agree	151 (76%)	49 (24%)	1.12 (0.85 - 1.48)	1.15 (0.87 - 1.51)
The queues to see a doctor or nurse are too long at this facility				
Disagree	211 (77%)	63 (23%)	Ref	Ref
Agree	538 (79%)	146 (21%)	0.93 (0.72 - 1.20)	0.94 (0.73 - 1.21)
In this clinic, you're able to talk to the doctors or nurses in private				
Disagree	97 (76%)	30 (24%)	Ref	Ref
Agree	704 (78%)	197 (22%)	0.93 (0.66 - 1.30)	0.92 (0.66 - 1.29)
The health workers are too busy to listen to my problems				
Disagree	728 (78%)	202 (22%)	Ref	Ref
Agree	72 (73%)	26 (27%)	1.22 (0.86 - 1.74)	1.25 (0.89 - 1.76)
The doctors and nurses discussed the treatment fully with me				
Disagree	43 (75%)	14 (25%)	Ref	Ref
Agree	767 (78%)	220 (22%)	0.91 (0.57 - 1.45)	0.90 (0.56 - 1.44)
I find it easy to tell the health workers when I have missed taking my tablets				

Characteristic	Continuously in care	Not continuously in care	Crude RR (95% CI)	Adjusted RR (95% CI)*
Disagree	146 (78%)	42 (22%)	Ref	Ref
Agree	573 (78%)	159 (22%)	0.97 (0.72 - 1.31)	0.95 (0.71 - 1.28)
The facilities are dirty				
Disagree	704 (78%)	195 (22%)	Ref	Ref
Agree	84 (74%)	30 (26%)	1.21 (0.87 -1.69)	1.26 (0.91 - 1.75)

267 \*Adjusted for age, gender, baseline CD4 count, and ART status at enrollment

268

269 *Qualitative findings*

270

271 When FGD participants were asked qualitatively about barriers to adherence in the first six months,  
 272 several key insights emerged at each social ecological level, though the majority pertained to  
 273 interpersonal and health facility levels (Table 5). At the individual level, key barriers were primarily  
 274 financial, though they affected continuity of care through different mechanisms. Participants reported  
 275 the cost of travel to the facility as a barrier that directly hampered their ability to obtain care and collect  
 276 medication. They also described general food scarcity which limited their willingness and ability to take  
 277 the medication for fear of side effects. Neither of these two financial barriers are surprising given that  
 278 over half of respondents in the analytic and FGD samples were unemployed at baseline and nearly a  
 279 quarter of respondents reported ‘sometimes/often’ experiencing food scarcity which was associated  
 280 with an increased likelihood of disengagement in the first six months.

281

282 **Table 5. Qualitative barriers to adherence in the early treatment period, fit to the social ecological**  
 283 **model**

284

Level	Barrier	Quotations
Individual	Financial cost of travel	"I have trouble with transportation money. My date arrives and I don't have money for transport. I even go and borrow from a friend."
	Food scarcity	"The medication intake requires one to eat food, when you do not have income to buy food, it really becomes a problem. I am discouraged to collect my medication from the clinic, because I know that I will not take it since there is no food, So I might as well stay without the pills because of the lack of income"
Interpersonal	Stigma deters people from disclosing their status to friends and loved ones;	"When I started taking treatment things changed at home. They had a discussion about me from day 1. I was given my own plate and spoon. I had my own things that I must use separately for everything I do in the house. So I am known as "that person on treatment" at home."
	feelings of ostracization within families and social circles.	"Sometimes it happens that in a family you are the only one like this. What scares me is that I am the only one in the family with this problem. I can't open up and talk to a person that is HIV negative and tell them I am positive. It would have been easier if somebody else was dealing with the same problem in my family"

"It is hard just to tell even friends what is going on and that you are on medication. Sometimes you end defaulting just to impress your family or the partner. You want to be seen as innocent to your partner."

Health facility Negative interactions with clinic staff; feeling shamed	<p>"Sometimes nurses come to the clinic with their own moods and attitudes and it becomes difficult to ask her about anything. It would be nice if you can walk in happy and leave happy. What happens sometimes is that you walk in well and leave feeling sick because the nurse who was attending to you has left you feeling stressed. You are even struggling to take instructions. "</p>
	<p>"But the problem started with the nurse who tested me.. When she finished testing me she was like "you are busy with boys here". She did not even know... So next time when they say go to the social worker, no thank you, because already you have judged me. You have categorised me, even if I was running around with boys, there was no need for you to say that."</p>
Inefficient filing system consumes staff time; results in multiple files per client and long wait times	<p>"The problem is the missing files at the clinics. They will come and ask when you last attended the clinic when it is clearly stated on the appointment card. I am not sure how files go missing, but they do. You sit for 30 minutes whilst they are still looking for your file. People behind you will pass you and go in. You end up being attended late. There really needs to be another strategy when it comes to the filing system."</p>
	<p>"My second and third visit were the same. My file was missing, I always have a new file and on subsequent visits the files will be all together and you just wonder where came from now. I had just to accept to have a lot of files."</p>
Clients perceive the lack of privacy they have at the clinic; fear of seeing someone you know	<p>"What makes people to be anxious about going to the clinic is meeting people they know that work at the clinic. They worry about them spreading the information to other people they know. They feel like hiding so that they will not be seen by people that know them at the clinic. It would help if clinic staff took the issue of confidentiality seriously. That is the reason people do not like going to the clinic."</p>
Community Work and opportunity costs of care seeking	<p>"My clinic date was on the 16th. My boss does not care if it is your clinic date. He wants you at work. So I wanted to leave work early but I couldn't. When I got of the taxi, it was already 16h00. I figured it was too late to go to the clinic. On the next day I woke up early to collect my treatment. When I got there I was number 2 but could not get assistance because there were prioritising people that came after me with appointment cards. I got angry and asked them what was happening and they said that I will be seen last because I missed the date."</p>
	<p>"Sometimes I will get the temporal job. I can't tell my boss that I have a temporal job. Even if I am given the day, when I come to the clinic at 8 o'clock, sometime I will get the treatment at past 2 or to 3. So, I would decide that it is better to go next week because I will stay without having something to eat and no money in my pocket and no nothing. Sometime I will prefer not to come because I have no</p>

---

money, plus the time I am going to spend at the clinic"

---

285  
286 At the interpersonal level, stigma and non-disclosure, two inextricably linked concepts, emerged as key  
287 barriers. Participants reported experiencing changes in how they were treated within their own homes  
288 and identified feelings of shame related to fear and gossip within their social networks. As illustrated in  
289 the quotes presented below, these feelings of stigma and shame can result in behaviors related to  
290 disengagement including non-disclosure or defaulting on treatment.

291  
292 Most of the barriers that emerged were at the facility level, wherein respondents reported negative  
293 interactions with health facility staff, inefficiencies in clinic processes, and a fear of disclosure because of  
294 a lack of privacy as demotivating factors that contributed to disengagement in the early treatment  
295 period. Respondents were frustrated with the processes of having to start a new file at every visit, which  
296 extended their wait time both while the provider searched for the old file and then started a new file.  
297 Respondents also explained that they experienced punitive repercussions for showing up a day or two  
298 late, including being shouted at or demoted to the back of the queue. Others described situations in  
299 which they felt they were being shamed or judged for having HIV.

300  
301 Finally, at the community level, barriers pertained to challenges associated with missing work multiple  
302 times for clinic appointments, as well as other opportunity costs associated with care-seeking.  
303 Participants described challenges negotiating time off from work to get to the clinic. This was a  
304 challenge both for those with permanent jobs and for those with temporary positions. Participants also  
305 described holding jobs that required them to travel which prevented them from getting to the clinic.

306

## 307 **Discussion**

308  
309 Reaching the second of UNAIDS's "three 95s" [19] --initiating and retaining 95% of known PLWH on ART--  
310 has remained challenging for high HIV burden countries like South Africa. Addressing high rates of  
311 disengagement from care after treatment initiation is likely the only effective pathway to achieving  
312 current targets [20]. To do this, obstacles to establishing and remaining continuously in care during the  
313 period with the highest risk for disengagement—patients' first six months on ART—must be identified  
314 and solutions to overcome these challenges explored.

315



316 Results of the PREFER study reported here confirmed high rates of disengagement during the early  
317 treatment period; overall nearly a quarter of participants were not continuously in care by 6 months  
318 after ART initiation, similar to rates of disengagement reported in other studies in South Africa [21]. A  
319 cyclical pattern of engagement characterized by an interruption in treatment of >28 days followed by re-  
320 engagement in care was more frequently observed during the early treatment period than was outright  
321 disengagement from care. Cyclical engagers in our cohort were most likely to have unsuppressed viral  
322 loads (>1000 copies/mL) at their six-month monitoring point, suggesting that they were indeed not  
323 accessing medication during the interruptions. This is consistent with other findings from South African  
324 cohorts suggesting poor treatment outcomes for returning engagers; one study found less than a third of  
325 clients maintain a suppressed VL one year after re-engaging in care [22] while another reported a four-  
326 fold increase in mortality risk among those who interrupt care during the first 6 months on ART [23].

327  
328 Quantitative results of our study identified some key groups that may require prioritization for retention  
329 interventions during the early treatment period. Not surprisingly, men, youth (18-24 years), and those  
330 newly initiating ART were groups most at risk for not bring continuously on ART by 6 months after  
331 treatment initiation. The first two populations are well-described demographic categories at risk of  
332 disengagement [24,25], while estimates for the latter group are likely impacted by survival bias –those in  
333 the study who had already returned for at least one clinic visit at the time of study enrollment had  
334 already been retained in care longer than the "immediate disengagers."

335  
336 We also found that those initiating a dolutegravir-based regimen at initiation were more likely to be  
337 continuously in care at 6 months than were those on efavirenz-based regimens. Dolutegravir-based  
338 regimens have been shown to be effective at rapidly suppressing virus and durable in terms of resistance  
339 development; clients also report fewer side effects on dolutegravir than other drug classes available in  
340 South Africa [26,27]. Also, not surprisingly, but less well documented in prior research, we found that  
341 clients in our study who either self-reported prior use of ART or were re-engaging in care at study  
342 enrolment were more likely to be receiving efavirenz-based ART. In this context, treatment regimen may  
343 be a proxy for prior treatment experience, as previously disengaging from care may be independently  
344 associated both with an efavirenz regimen and an increased risk for a subsequent treatment interruption  
345 if the factors leading to the first episode of disengagement are not addressed.

346

347 While these findings are consistent with other work and begin to identify groups to prioritize, they offer  
348 few practical solutions. Although they are considered the highest risk groups, an absolute majority of  
349 men, young people, and previous disengagers do remain continuously in care (i.e. continuous retention  
350 exceeds 50%) and do not require additional intervention to achieve viral suppression. There is a need to  
351 get beyond these general characteristics if we are to identify important and modifiable drivers of  
352 disengagement and find feasible solutions. PREFER made some progress in this direction. We found that  
353 food scarcity and the use of an efavirenz-based regimen were both associated with a significant  
354 reduction in continuous engagement. While our estimates lacked precision, we also observed that  
355 participants with unfavorable views of their treatment experience--long waiting queues and negative  
356 interactions with healthcare workers, such as clients who report re-engaging in care being attended to  
357 after all other booked clients--were also less likely to remain continuously engaged. Finally, as expected,  
358 we observed high immediate disengagement from care (no further visits after initiation), indicating that  
359 for many clients, the initiation visit itself offers the only chance to influence later outcomes.

360  
361 The qualitative findings offered further insights in this regard, while also reinforcing existing evidence  
362 about the patient-provider relationship [28–30]. Despite two decades of societal experience with HIV  
363 treatment since the rollout of ART in South Africa, study participants reported that stigma and social  
364 ostracization remain major impediments to treatment continuity. Clients reported this barrier both in  
365 their homes and at facilities, where negative language and shaming of clients living with HIV persists and  
366 privacy may be compromised. Another key facility-level barrier to visit adherence that clients reported  
367 was the inefficiencies created by poorly organized filing systems that result in loss of client information,  
368 duplicate files, and excessive waiting times at each facility visit.

369  
370 While societal stigma is not easily addressed, many of the facility-level barriers identified in our study are  
371 modifiable within the healthcare system. A systematic review of interventions to improve retention [31]  
372 found positive benefits of community-based service delivery and adherence clubs, bearing in mind that  
373 the models reviewed were underpinned by supportive interventions that addressed psychosocial  
374 barriers to adherence. Positive motivational counselling skills development [32] has been shown to  
375 improve provider-client relationships and subsequent retention and viral suppression [33]. Though  
376 primarily directed at lay counsellors, application of person-centered language and approaches across all  
377 facility staff cadres could positively affect client experience and thus long term and continuous

378 engagement in care. Low-intensity models of care for established ART clients may reduce pressure on  
379 providers and allow them to spend more time with initiating and new patients [34].

380  
381 Our results also identified financial constraints as a barrier to continuity of HIV care and treatment. Both  
382 the quantitative and qualitative results indicated that clients frequently found it difficult to obtain the  
383 cash needed to access health care at the prescribed intervals. Transport costs were most often noted,  
384 but other costs, such as child care, loss of income due to missing work for a day, and purchasing of food  
385 and drinks while waiting in queues, also present difficulties for clients who must make frequent clinic  
386 visits during the first 6 months on ART. While financial incentives have been shown to improve rates of  
387 retention and viral suppression in the first 6 months on ART [35], it is unclear whether these incentives  
388 result in sustained continuity of care and if an intervention like this could be sustainably scaled in a  
389 national program as large as South Africa's.

390  
391 Many of the barriers that impede engagement in the early treatment period could potentially be  
392 addressed by existing service delivery options found within many countries' differentiated service  
393 delivery programs. Early period patients may benefit from fast-tracking, multi-month dispensing, and  
394 flexibility of location for medication pickups as much as, if not more than, established patients.  
395 Recognizing this potential, South Africa's most recent update to its national guidelines [36] introduces an  
396 initial viral load monitoring test at 3 months after initiation, rather than the usual six. This change  
397 effectively brings forward eligibility for a differentiated model of service delivery forward to 4 months  
398 after initiation, the first routine clinic visit at which viral load test results are available. For clients who  
399 remain in care for the first four months, this is a promising improvement. As noted, however, most  
400 disengagement during the early treatment period occurs within the first 3 months.

401  
402 Our study had a number of limitations. First, the sample size was modest, in terms of both number of  
403 study sites and number of participants, and generalizability to districts and provinces not included in the  
404 survey will require caution. Second, study clients were enrolled at any point up to 6 months after ART  
405 initiation, which may have created the possibility of recall bias for questions pertaining to their  
406 experiences and perceptions at ART initiation. As mentioned above, this enrollment strategy also  
407 potentially created a survival bias in our outcome results. We note, for example, that 86% of PREFER  
408 study participants had WHO stage recorded as Stage 1. This may reflect the need for clients to be well  
409 enough to participate in the study, resulting in exclusion of some of those with Stage 3 or 4 defining

410 conditions. While we cannot exclude this possibility, we note that nearly a quarter (24%) of those  
411 enrolled presented with CD4 counts <200, the immunologic definition for advanced HIV disease, which is  
412 consistent with other estimates of AHD populations [37]. Third, we used participant self-report to  
413 determine prior ART use, which has previously been observed to be subject to much under-reporting;  
414 estimates suggest that anywhere from 20-50% of clients presenting for initiation of ART have previously  
415 used ART before [38]. To the extent to which this exposure misclassification occurred in the PREFER  
416 sample, our results will under-estimate the effect of prior ART use on risk of disengagement from care.  
417 Finally, we relied on routinely collected EMR data to ascertain participant ART retention outcomes at 6  
418 months after ART initiation. This approach may also introduce bias due to outcome misclassification as  
419 our data is limited to visits observed at the initiating facility--we did not observe participants accessing  
420 care at other facilities. To the extent to which silent transfers such as these have occurred, our results  
421 will over-estimate rates of disengagement.

422

## 423 **Conclusion**

424

425 Despite these limitations, this study identified a number of potentially modifiable factors that, if  
426 addressed, could improve early HIV treatment outcomes, in particular, improving clients' experiences at  
427 healthcare facilities and offering less expensive access to care, in terms of both time and transport costs.  
428 Accelerating eligibility for DSD models, so that even new ART clients can pick up medications at  
429 convenient locations and receive larger quantities of medications at a time, offers one way to address  
430 some of these issues. Strengthening the implementation of the 2023 revision to the National ART  
431 Guidelines [16], particularly with regard to CD4 count and viral load monitoring, could assist in  
432 identification and support of clients with advanced HIV disease and those eligible for earlier enrollment  
433 in differentiated service delivery options. While we did not identify a silver bullet for targeting clients at  
434 risk of disengagement, we began to describe subgroups who may benefit from more attention, such as  
435 previous disengagers. We hope that future research will further explore the characteristics of those who  
436 do, and do not, need intervention to achieve successful outcomes.

437

## 438 **Conflict of interest statement**

439

440 The authors have no conflicts of interest to declare. Drs. Manganye and Malala are employees of the  
441 government agency that has supervisory authority over the study sites.

442

443 **Authors' contributions**

444

445 MM, NS, LS, and SR conceived of and designed the study. NM, AM, and MB analyzed the data. VN  
446 supervised data collection. LM and MM contributed to interpretation of results. MM, NS, AM, and SR  
447 drafted the manuscript. All authors have read and approved the final manuscript.

448

449 **Acknowledgements**

450

451 We would like to thank the clients and staff of the study sites for their cooperation in allowing us to  
452 conduct this study and the South Africa National Department of Health (NDOH) for approving this  
453 research.

454

455 **Data availability**

456

457 Data generated by the study will be made publicly available in the Open BU repository  
458 (<https://open.bu.edu/>) after the PREFER study protocol has been closed (anticipated closure December  
459 2025). Until then, data will remain under the supervision of the Boston University Medical Campus IRB  
460 and the University of the Witwatersrand Human Research Ethics Committee (HREC). Requests can be  
461 sent to the BUMC IRB at [medirb@bu.edu](mailto:medirb@bu.edu). Data extracted from routine medical records are owned by the  
462 study sites and the South African National Department of Health and cannot be made publicly available  
463 by the authors.

464

465 **Funding**

466

467 Funding for the study was provided by the Bill & Melinda Gates Foundation through INV-031690 to  
468 Boston University. The funder had no role in study design, data collection and analysis, decision to  
469 publish, or preparation of the manuscript.

470

471 **Ethics**

472

473 The PREFER study was approved by the Boston University Institutional Review Board (South Africa H-  
474 42726, May 20, 2022) and by the University of the Witwatersrand Human Research Ethics Committee  
475 (South Africa M220440, August 23, 2022). The protocol for South Africa was approved by Provincial  
476 Health Research Committees through the National Health Research Database for each study district  
477 (August 1, 2022 for West Rand; September 1, 2022 for King Cetshwayo and August 28, 2022 for  
478 Ehlanzeni). The study is registered with ClinicalTrials.gov (NCT05454839).  
479

480 **References**

- 481 1. Fox MP, Rosen S. A new cascade of HIV care for the era of “treat all.” *PLoS Med.* 2017;14:  
482 e1002268. doi:10.1371/journal.pmed.1002268
- 483 2. Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a  
484 patient’s first six months on antiretroviral therapy for HIV: an applied research agenda.  
485 *Gates Open Res.* 2020;4: 116.
- 486 3. Maskew M, Benade M, Huber A, Pascoe S, Sande L, Malala L, et al. Patterns of  
487 engagement in care during clients’ first 12 months after HIV treatment initiation in South  
488 Africa: A retrospective cohort analysis using routinely collected data. *PLOS Global Public*  
489 *Health.* 2024;4: e0002956. doi:10.1371/journal.pgph.0002956
- 490 4. Lilian RR, Rees K, Mabitsi M, McIntyre JA, Struthers HE, Peters RPH. Baseline CD4 and  
491 mortality trends in the South African human immunodeficiency virus programme:  
492 Analysis of routine data. *South Afr J HIV Med.* 2019;20: 1–10.  
493 doi:10.4102/sajhivmed.v20i1.963
- 494 5. Zaniewski E, Dao Ostinelli CH, Chammartin F, Maxwell N, Davies MA, Euvrard J, et al.  
495 Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living  
496 with HIV in Southern Africa. *J Int AIDS Soc.* 2020;23: 1–10. doi:10.1002/jia2.25546
- 497 6. World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid  
498 Initiation of Antiretroviral Therapy. 2017. Available:  
499 <https://www.who.int/publications/i/item/9789241550062>
- 500 7. Benade M, Maskew M, Juntunen A, Flynn DB, Rosen S. Prior exposure to antiretroviral  
501 therapy among adult patients presenting for HIV treatment initiation or reinitiation in  
502 sub-Saharan Africa: a systematic review. *BMJ Open.* 2023;13: e071283.  
503 doi:10.1136/bmjopen-2022-071283
- 504 8. Mavhandu-Ramarumo LG, Tambe LAM, Matume ND, Katerere D, Bessong PO.  
505 Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory  
506 analysis. *South Afr J HIV Med.* 2021;22: 1–10. doi:10.4102/sajhivmed.v22i1.1200

- 507 9. leDEA and COHERE Cohort Collaborations. Global Trends in CD4 Cell Count at the Start of  
508 Antiretroviral Therapy: Collaborative Study of Treatment Programs. *Clinical Infectious*  
509 *Diseases*. 2018 [cited 6 Feb 2018]. doi:10.1093/cid/cix915
- 510 10. Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, et al. Benefits and  
511 risks of rapid initiation of antiretroviral therapy. *Aids*. 2017;0: 1.  
512 doi:10.1097/QAD.0000000000001671
- 513 11. Ehrenkranz P, Grimsrud A, Rabkin M. Differentiated service delivery: Navigating the path  
514 to scale. *Curr Opin HIV AIDS*. 2019;14: 60–65. doi:10.1097/COH.0000000000000509
- 515 12. Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a  
516 patient’s first six months on antiretroviral therapy for HIV: An applied research agenda.  
517 *Gates Open Res*. 2020;4: 1–15. doi:10.12688/gatesopenres.13159.1
- 518 13. Maskew M, Ntjikelane V, Juntunen A, Scott N, Benade M, Sande L, et al. Preferences for  
519 services in a patient’s first six months on antiretroviral therapy for HIV in South Africa and  
520 Zambia (PREFER): research protocol for a prospective observational cohort study. *Gates*  
521 *Open Res*. 2023;7: 119. doi:10.12688/gatesopenres.14682.1
- 522 14. National Department of Health. 2019 ART Clinical Guidelines. Pretoria; 2019.
- 523 15. National Department of Health. Adherence guidelines for HIV, TB and NCDS, updated  
524 March 2020. Standard operating procedures: minimum package of interventions to  
525 support linkage to care, adherence and retention. 2020.
- 526 16. National Department of Health. Minimum package of interventions to support linkage to  
527 care, adherence and retention in care standard operating procedures. 2023.
- 528 17. Kilanowski JF. Breadth of the Socio-Ecological Model. *Journal of Agromedicine*. Taylor and  
529 Francis Ltd.; 2017. pp. 295–297. doi:10.1080/1059924X.2017.1358971
- 530 18. Wanjala SW, Nyongesa MK, Luchters S, Abubakar A. Psychosocial and mental health  
531 challenges facing perinatally HIV-infected adolescents along the Kenyan coast: a  
532 qualitative inquiry using the socioecological model. *Front Public Health*. 2024;12:  
533 1379262. doi:10.3389/fpubh.2024.1379262
- 534 19. Joint United Nations Programme on HIV/AIDS (UNAIDS). Understanding measures of  
535 progress towards the 95–95–95 HIV testing, treatment and viral suppression targets.



- 536 2023; 1–2. Available: [https://www.unaids.org/en/resources/documents/2024/progress-](https://www.unaids.org/en/resources/documents/2024/progress-towards-95-95-95)  
537 [towards-95-95-95](https://www.unaids.org/en/resources/documents/2024/progress-towards-95-95-95)
- 538 20. Meyer-Rath G, Jamieson L, Johnson LF. When the only intervention left to optimise is  
539 retention: Comparing the 2021 and 2016 South African HIV Investment Cases.
- 540 21. Benade M, Maskew M, Chilembo P, Mwanza WM, Sande L, Rosen S. Patterns of  
541 engagement in care during clients’ first 12 months after HIV treatment initiation in South  
542 Africa: A retrospective cohort analysis using routinely collected data. AIDS 2024. Munich,  
543 Germany; 2024.
- 544 22. Keene CM, Euvrard J, Cassidy T, English M, Mcknight J, Orrell C, et al. Persistent  
545 Challenges with Viral Suppression a Year After Return to Care: Evidence from South  
546 Africa.
- 547 23. Moolla H, Davies MA, Davies C, Euvrard J, Prozesky HW, Fox MP, et al. The effect of care  
548 interruptions on mortality in adults resuming antiretroviral therapy. AIDS. 2024;38: 1198–  
549 1205. doi:10.1097/QAD.0000000000003859
- 550 24. Makurumidze R, Decroo T, Jacobs BKM, Rusakaniko S, Van Damme W, Lynen L, et al.  
551 Attrition one year after starting antiretroviral therapy before and after the programmatic  
552 implementation of HIV “Treat All” in Sub-Saharan Africa: a systematic review and meta-  
553 analysis. BMC Infect Dis. 2023;23: 558. doi:10.1186/s12879-023-08551-y
- 554 25. Frijters EM, Hermans LE, Wensing AMJ, Devillé WLJM, Tempelman HA, De Wit JBF. Risk  
555 factors for loss to follow-up from antiretroviral therapy programmes in low-income and  
556 middle-income countries. AIDS. 2020;34: 1261–1288.  
557 doi:10.1097/QAD.0000000000002523
- 558 26. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Mbombi MO, et al.  
559 Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med.  
560 2019;381: 803–815. doi:10.1056/NEJMoa1902824
- 561 27. NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P,  
562 Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A DE. Dolutegravir-Based or Low-  
563 Dose Efavirenz– Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019;381: 816–  
564 826. doi:10.1056/NEJMoa1904340

- 565 28. George S, McGrath N. Social support, disclosure and stigma and the association with non-  
566 adherence in the six months after antiretroviral therapy initiation among a cohort of HIV-  
567 positive adults in rural KwaZulu-Natal, South Africa. *AIDS Care*. 2019;31: 875–884.  
568 doi:10.1080/09540121.2018.1549720
- 569 29. Killian C, West RL, Orrell C, Gifford A, Haberer JE, Halim N, et al. Negative clinic  
570 experiences as a barrier to care for people with HIV and their impact on patient  
571 preferences for intervention support: a qualitative study in Cape Town, South Africa. *AIDS*  
572 *Care*. 2024;36: 1222–1231. doi:10.1080/09540121.2024.2346255
- 573 30. Zanolini A, Sikombe K, Sikazwe I, Eshun-Wilson I, Somwe P, Bolton Moore C, et al.  
574 Understanding preferences for HIV care and treatment in Zambia: Evidence from a  
575 discrete choice experiment among patients who have been lost to follow-up. Tsai AC,  
576 editor. *PLoS Med*. 2018;15: e1002636. doi:10.1371/journal.pmed.1002636
- 577 31. Penn AW, Azman H, Horvath H, Taylor KD, Hickey MD, Rajan J, et al. Supportive  
578 interventions to improve retention on ART in people with HIV in low- and middle-income  
579 countries: A systematic review. *PLoS One*. 2018;13. doi:10.1371/JOURNAL.PONE.0208814
- 580 32. Mokhele I, Sineke T, Vujovic M, Ruiters RAC, Miot J, Onoya D. Improving patient-centred  
581 counselling skills among lay healthcare workers in South Africa using the Thusa-Thuso  
582 motivational interviewing training and support program. *PLOS Global Public Health*.  
583 2024;4: 1–17. doi:10.1371/journal.pgph.0002611
- 584 33. Onoya D, Sineke T, Mokhele I, Vujovic M, Holland K, Ruiters RAC. Improving Retention and  
585 HIV Viral Suppression: A Cluster Randomised Pilot Trial of a Lay Counsellor Motivational  
586 Interviewing Training in South Africa. *medRxiv*. 2024; 1–30.  
587 doi:10.1101/2024.09.20.24314048
- 588 34. CCMDD in South Africa: provider workload, responsibilities, and time use. Johannesburg;  
589 2023 Jun.
- 590 35. Fahey CA, Njau PF, Katabaro E, Mfaume RS, Ulenga N, Mwenda N, et al. Financial  
591 incentives to promote retention in care and viral suppression in adults with HIV initiating  
592 antiretroviral therapy in Tanzania: a three-arm randomised controlled trial. *Lancet HIV*.  
593 2020;7: e762–e771. doi:10.1016/S2352-3018(20)30230-7

- 594 36. South African National Department of Health. 2023 ART Clinical Guidelines for the  
595 Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children,  
596 Infants and Neonates. 2023. Available:  
597 [//www.knowledgehub.org.za/system/files/elibdownloads/2020-05/2019 ART Guideline](http://www.knowledgehub.org.za/system/files/elibdownloads/2020-05/2019_ART_Guideline_28042020.pdf)  
598 [28042020 pdf.pdf](http://www.knowledgehub.org.za/system/files/elibdownloads/2020-05/2019_ART_Guideline_28042020.pdf)
- 599 37. de Waal R, Wools-Kaloustian K, Brazier E, Althoff KN, Jaquet A, Duda SN, et al. Global  
600 trends in CD4 count measurement and distribution at first antiretroviral treatment  
601 initiation. *Clin Infect Dis*. 2024. doi:10.1093/cid/ciae548
- 602 38. Benade M, Maskew M, Juntunen A, Flynn DB, Rosen S. Prior exposure to antiretroviral  
603 therapy among adult patients presenting for HIV treatment initiation or reinitiation in  
604 sub-Saharan Africa: A systematic review. *BMJ Open*. 2023;13: 1–11.  
605 doi:10.1136/bmjopen-2022-071283  
606